Describe the efficacy of the use of topical besifloxacin in reducing the conjunctival microbiota as a prophylactic measure in patients scheduled for cataract surgery.

Randomized double-blind clinical trial. Study carried out in a single center between January and April 2017. 60 eyes were included that were randomly divided in a 1: 1 ratio into two groups. The first group received placebo (hydroxypropylmethylcellulose drops) while the second group received 0.6% besifloxacin drops four times a day for 3 days. All of them had a conjunctival cul-de-sac culture before and after treatment.

Inclusion Criteria:

• Subjects over 18 years of age scheduled for cataract surgery in the established study period.
• Subjects physically and mentally capable of applying the eye drops or having a person available to help in the correct administration of the eye drops 4 times a day.

Exclusion Criteria:

• - Active eye infection (bacterial, viral, fungal or parasitic) such as blepharitis and / or conjunctivitis.
• Known allergy or any contraindication to the use of quinolones or any of the components of the drugs.